Global Ipilimumab Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Ipilimumab is a monoclonal antibody, more specifically a fully humanized IgG1 antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint.
LPI (LP Information)' newest research report, the “Ipilimumab Industry Forecast” looks at past sales and reviews total world Ipilimumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Ipilimumab sales for 2023 through 2029. With Ipilimumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ipilimumab industry.
This Insight Report provides a comprehensive analysis of the global Ipilimumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ipilimumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Ipilimumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ipilimumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ipilimumab.
The global Ipilimumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Ipilimumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Ipilimumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Ipilimumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Ipilimumab players cover Gilead, BMS, Ono, Roche, Prestige BioPharma, Avacta, Baxter and Shenyang Sansheng Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Ipilimumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Ipilimumab market?
What factors are driving Ipilimumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ipilimumab market opportunities vary by end market size?
How does Ipilimumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Ipilimumab is a monoclonal antibody, more specifically a fully humanized IgG1 antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint.
LPI (LP Information)' newest research report, the “Ipilimumab Industry Forecast” looks at past sales and reviews total world Ipilimumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Ipilimumab sales for 2023 through 2029. With Ipilimumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ipilimumab industry.
This Insight Report provides a comprehensive analysis of the global Ipilimumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ipilimumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Ipilimumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ipilimumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ipilimumab.
The global Ipilimumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Ipilimumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Ipilimumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Ipilimumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Ipilimumab players cover Gilead, BMS, Ono, Roche, Prestige BioPharma, Avacta, Baxter and Shenyang Sansheng Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Ipilimumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- PD - L1 Antagonists
- CTLA4 Antagonists
- Immunocheckpoint Inhibitors
- Other
- Cancer
- Melanoma
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Gilead
- BMS
- Ono
- Roche
- Prestige BioPharma
- Avacta
- Baxter
- Shenyang Sansheng Pharmaceutical
What is the 10-year outlook for the global Ipilimumab market?
What factors are driving Ipilimumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ipilimumab market opportunities vary by end market size?
How does Ipilimumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ipilimumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Ipilimumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Ipilimumab by Country/Region, 2018, 2022 & 2029
2.2 Ipilimumab Segment by Type
2.2.1 PD - L1 Antagonists
2.2.2 CTLA4 Antagonists
2.2.3 Immunocheckpoint Inhibitors
2.2.4 Other
2.3 Ipilimumab Sales by Type
2.3.1 Global Ipilimumab Sales Market Share by Type (2018-2023)
2.3.2 Global Ipilimumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Ipilimumab Sale Price by Type (2018-2023)
2.4 Ipilimumab Segment by Application
2.4.1 Cancer
2.4.2 Melanoma
2.5 Ipilimumab Sales by Application
2.5.1 Global Ipilimumab Sale Market Share by Application (2018-2023)
2.5.2 Global Ipilimumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Ipilimumab Sale Price by Application (2018-2023)
3 GLOBAL IPILIMUMAB BY COMPANY
3.1 Global Ipilimumab Breakdown Data by Company
3.1.1 Global Ipilimumab Annual Sales by Company (2018-2023)
3.1.2 Global Ipilimumab Sales Market Share by Company (2018-2023)
3.2 Global Ipilimumab Annual Revenue by Company (2018-2023)
3.2.1 Global Ipilimumab Revenue by Company (2018-2023)
3.2.2 Global Ipilimumab Revenue Market Share by Company (2018-2023)
3.3 Global Ipilimumab Sale Price by Company
3.4 Key Manufacturers Ipilimumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ipilimumab Product Location Distribution
3.4.2 Players Ipilimumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR IPILIMUMAB BY GEOGRAPHIC REGION
4.1 World Historic Ipilimumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Ipilimumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Ipilimumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Ipilimumab Market Size by Country/Region (2018-2023)
4.2.1 Global Ipilimumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Ipilimumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Ipilimumab Sales Growth
4.4 APAC Ipilimumab Sales Growth
4.5 Europe Ipilimumab Sales Growth
4.6 Middle East & Africa Ipilimumab Sales Growth
5 AMERICAS
5.1 Americas Ipilimumab Sales by Country
5.1.1 Americas Ipilimumab Sales by Country (2018-2023)
5.1.2 Americas Ipilimumab Revenue by Country (2018-2023)
5.2 Americas Ipilimumab Sales by Type
5.3 Americas Ipilimumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ipilimumab Sales by Region
6.1.1 APAC Ipilimumab Sales by Region (2018-2023)
6.1.2 APAC Ipilimumab Revenue by Region (2018-2023)
6.2 APAC Ipilimumab Sales by Type
6.3 APAC Ipilimumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ipilimumab by Country
7.1.1 Europe Ipilimumab Sales by Country (2018-2023)
7.1.2 Europe Ipilimumab Revenue by Country (2018-2023)
7.2 Europe Ipilimumab Sales by Type
7.3 Europe Ipilimumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ipilimumab by Country
8.1.1 Middle East & Africa Ipilimumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Ipilimumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Ipilimumab Sales by Type
8.3 Middle East & Africa Ipilimumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ipilimumab
10.3 Manufacturing Process Analysis of Ipilimumab
10.4 Industry Chain Structure of Ipilimumab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ipilimumab Distributors
11.3 Ipilimumab Customer
12 WORLD FORECAST REVIEW FOR IPILIMUMAB BY GEOGRAPHIC REGION
12.1 Global Ipilimumab Market Size Forecast by Region
12.1.1 Global Ipilimumab Forecast by Region (2024-2029)
12.1.2 Global Ipilimumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ipilimumab Forecast by Type
12.7 Global Ipilimumab Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Gilead
13.1.1 Gilead Company Information
13.1.2 Gilead Ipilimumab Product Portfolios and Specifications
13.1.3 Gilead Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Gilead Main Business Overview
13.1.5 Gilead Latest Developments
13.2 BMS
13.2.1 BMS Company Information
13.2.2 BMS Ipilimumab Product Portfolios and Specifications
13.2.3 BMS Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 BMS Main Business Overview
13.2.5 BMS Latest Developments
13.3 Ono
13.3.1 Ono Company Information
13.3.2 Ono Ipilimumab Product Portfolios and Specifications
13.3.3 Ono Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Ono Main Business Overview
13.3.5 Ono Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Ipilimumab Product Portfolios and Specifications
13.4.3 Roche Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Prestige BioPharma
13.5.1 Prestige BioPharma Company Information
13.5.2 Prestige BioPharma Ipilimumab Product Portfolios and Specifications
13.5.3 Prestige BioPharma Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Prestige BioPharma Main Business Overview
13.5.5 Prestige BioPharma Latest Developments
13.6 Avacta
13.6.1 Avacta Company Information
13.6.2 Avacta Ipilimumab Product Portfolios and Specifications
13.6.3 Avacta Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Avacta Main Business Overview
13.6.5 Avacta Latest Developments
13.7 Baxter
13.7.1 Baxter Company Information
13.7.2 Baxter Ipilimumab Product Portfolios and Specifications
13.7.3 Baxter Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Baxter Main Business Overview
13.7.5 Baxter Latest Developments
13.8 Shenyang Sansheng Pharmaceutical
13.8.1 Shenyang Sansheng Pharmaceutical Company Information
13.8.2 Shenyang Sansheng Pharmaceutical Ipilimumab Product Portfolios and Specifications
13.8.3 Shenyang Sansheng Pharmaceutical Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Shenyang Sansheng Pharmaceutical Main Business Overview
13.8.5 Shenyang Sansheng Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ipilimumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Ipilimumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Ipilimumab by Country/Region, 2018, 2022 & 2029
2.2 Ipilimumab Segment by Type
2.2.1 PD - L1 Antagonists
2.2.2 CTLA4 Antagonists
2.2.3 Immunocheckpoint Inhibitors
2.2.4 Other
2.3 Ipilimumab Sales by Type
2.3.1 Global Ipilimumab Sales Market Share by Type (2018-2023)
2.3.2 Global Ipilimumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Ipilimumab Sale Price by Type (2018-2023)
2.4 Ipilimumab Segment by Application
2.4.1 Cancer
2.4.2 Melanoma
2.5 Ipilimumab Sales by Application
2.5.1 Global Ipilimumab Sale Market Share by Application (2018-2023)
2.5.2 Global Ipilimumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Ipilimumab Sale Price by Application (2018-2023)
3 GLOBAL IPILIMUMAB BY COMPANY
3.1 Global Ipilimumab Breakdown Data by Company
3.1.1 Global Ipilimumab Annual Sales by Company (2018-2023)
3.1.2 Global Ipilimumab Sales Market Share by Company (2018-2023)
3.2 Global Ipilimumab Annual Revenue by Company (2018-2023)
3.2.1 Global Ipilimumab Revenue by Company (2018-2023)
3.2.2 Global Ipilimumab Revenue Market Share by Company (2018-2023)
3.3 Global Ipilimumab Sale Price by Company
3.4 Key Manufacturers Ipilimumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ipilimumab Product Location Distribution
3.4.2 Players Ipilimumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR IPILIMUMAB BY GEOGRAPHIC REGION
4.1 World Historic Ipilimumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Ipilimumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Ipilimumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Ipilimumab Market Size by Country/Region (2018-2023)
4.2.1 Global Ipilimumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Ipilimumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Ipilimumab Sales Growth
4.4 APAC Ipilimumab Sales Growth
4.5 Europe Ipilimumab Sales Growth
4.6 Middle East & Africa Ipilimumab Sales Growth
5 AMERICAS
5.1 Americas Ipilimumab Sales by Country
5.1.1 Americas Ipilimumab Sales by Country (2018-2023)
5.1.2 Americas Ipilimumab Revenue by Country (2018-2023)
5.2 Americas Ipilimumab Sales by Type
5.3 Americas Ipilimumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ipilimumab Sales by Region
6.1.1 APAC Ipilimumab Sales by Region (2018-2023)
6.1.2 APAC Ipilimumab Revenue by Region (2018-2023)
6.2 APAC Ipilimumab Sales by Type
6.3 APAC Ipilimumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ipilimumab by Country
7.1.1 Europe Ipilimumab Sales by Country (2018-2023)
7.1.2 Europe Ipilimumab Revenue by Country (2018-2023)
7.2 Europe Ipilimumab Sales by Type
7.3 Europe Ipilimumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ipilimumab by Country
8.1.1 Middle East & Africa Ipilimumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Ipilimumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Ipilimumab Sales by Type
8.3 Middle East & Africa Ipilimumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ipilimumab
10.3 Manufacturing Process Analysis of Ipilimumab
10.4 Industry Chain Structure of Ipilimumab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ipilimumab Distributors
11.3 Ipilimumab Customer
12 WORLD FORECAST REVIEW FOR IPILIMUMAB BY GEOGRAPHIC REGION
12.1 Global Ipilimumab Market Size Forecast by Region
12.1.1 Global Ipilimumab Forecast by Region (2024-2029)
12.1.2 Global Ipilimumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ipilimumab Forecast by Type
12.7 Global Ipilimumab Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Gilead
13.1.1 Gilead Company Information
13.1.2 Gilead Ipilimumab Product Portfolios and Specifications
13.1.3 Gilead Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Gilead Main Business Overview
13.1.5 Gilead Latest Developments
13.2 BMS
13.2.1 BMS Company Information
13.2.2 BMS Ipilimumab Product Portfolios and Specifications
13.2.3 BMS Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 BMS Main Business Overview
13.2.5 BMS Latest Developments
13.3 Ono
13.3.1 Ono Company Information
13.3.2 Ono Ipilimumab Product Portfolios and Specifications
13.3.3 Ono Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Ono Main Business Overview
13.3.5 Ono Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Ipilimumab Product Portfolios and Specifications
13.4.3 Roche Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Prestige BioPharma
13.5.1 Prestige BioPharma Company Information
13.5.2 Prestige BioPharma Ipilimumab Product Portfolios and Specifications
13.5.3 Prestige BioPharma Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Prestige BioPharma Main Business Overview
13.5.5 Prestige BioPharma Latest Developments
13.6 Avacta
13.6.1 Avacta Company Information
13.6.2 Avacta Ipilimumab Product Portfolios and Specifications
13.6.3 Avacta Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Avacta Main Business Overview
13.6.5 Avacta Latest Developments
13.7 Baxter
13.7.1 Baxter Company Information
13.7.2 Baxter Ipilimumab Product Portfolios and Specifications
13.7.3 Baxter Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Baxter Main Business Overview
13.7.5 Baxter Latest Developments
13.8 Shenyang Sansheng Pharmaceutical
13.8.1 Shenyang Sansheng Pharmaceutical Company Information
13.8.2 Shenyang Sansheng Pharmaceutical Ipilimumab Product Portfolios and Specifications
13.8.3 Shenyang Sansheng Pharmaceutical Ipilimumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Shenyang Sansheng Pharmaceutical Main Business Overview
13.8.5 Shenyang Sansheng Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Ipilimumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Ipilimumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of PD - L1 Antagonists
Table 4. Major Players of CTLA4 Antagonists
Table 5. Major Players of Immunocheckpoint Inhibitors
Table 6. Major Players of Other
Table 7. Global Ipilimumab Sales by Type (2018-2023) & (KG)
Table 8. Global Ipilimumab Sales Market Share by Type (2018-2023)
Table 9. Global Ipilimumab Revenue by Type (2018-2023) & ($ million)
Table 10. Global Ipilimumab Revenue Market Share by Type (2018-2023)
Table 11. Global Ipilimumab Sale Price by Type (2018-2023) & (US$/G)
Table 12. Global Ipilimumab Sales by Application (2018-2023) & (KG)
Table 13. Global Ipilimumab Sales Market Share by Application (2018-2023)
Table 14. Global Ipilimumab Revenue by Application (2018-2023)
Table 15. Global Ipilimumab Revenue Market Share by Application (2018-2023)
Table 16. Global Ipilimumab Sale Price by Application (2018-2023) & (US$/G)
Table 17. Global Ipilimumab Sales by Company (2018-2023) & (KG)
Table 18. Global Ipilimumab Sales Market Share by Company (2018-2023)
Table 19. Global Ipilimumab Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Ipilimumab Revenue Market Share by Company (2018-2023)
Table 21. Global Ipilimumab Sale Price by Company (2018-2023) & (US$/G)
Table 22. Key Manufacturers Ipilimumab Producing Area Distribution and Sales Area
Table 23. Players Ipilimumab Products Offered
Table 24. Ipilimumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Ipilimumab Sales by Geographic Region (2018-2023) & (KG)
Table 28. Global Ipilimumab Sales Market Share Geographic Region (2018-2023)
Table 29. Global Ipilimumab Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Ipilimumab Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Ipilimumab Sales by Country/Region (2018-2023) & (KG)
Table 32. Global Ipilimumab Sales Market Share by Country/Region (2018-2023)
Table 33. Global Ipilimumab Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Ipilimumab Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Ipilimumab Sales by Country (2018-2023) & (KG)
Table 36. Americas Ipilimumab Sales Market Share by Country (2018-2023)
Table 37. Americas Ipilimumab Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Ipilimumab Revenue Market Share by Country (2018-2023)
Table 39. Americas Ipilimumab Sales by Type (2018-2023) & (KG)
Table 40. Americas Ipilimumab Sales by Application (2018-2023) & (KG)
Table 41. APAC Ipilimumab Sales by Region (2018-2023) & (KG)
Table 42. APAC Ipilimumab Sales Market Share by Region (2018-2023)
Table 43. APAC Ipilimumab Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Ipilimumab Revenue Market Share by Region (2018-2023)
Table 45. APAC Ipilimumab Sales by Type (2018-2023) & (KG)
Table 46. APAC Ipilimumab Sales by Application (2018-2023) & (KG)
Table 47. Europe Ipilimumab Sales by Country (2018-2023) & (KG)
Table 48. Europe Ipilimumab Sales Market Share by Country (2018-2023)
Table 49. Europe Ipilimumab Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Ipilimumab Revenue Market Share by Country (2018-2023)
Table 51. Europe Ipilimumab Sales by Type (2018-2023) & (KG)
Table 52. Europe Ipilimumab Sales by Application (2018-2023) & (KG)
Table 53. Middle East & Africa Ipilimumab Sales by Country (2018-2023) & (KG)
Table 54. Middle East & Africa Ipilimumab Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Ipilimumab Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Ipilimumab Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Ipilimumab Sales by Type (2018-2023) & (KG)
Table 58. Middle East & Africa Ipilimumab Sales by Application (2018-2023) & (KG)
Table 59. Key Market Drivers & Growth Opportunities of Ipilimumab
Table 60. Key Market Challenges & Risks of Ipilimumab
Table 61. Key Industry Trends of Ipilimumab
Table 62. Ipilimumab Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Ipilimumab Distributors List
Table 65. Ipilimumab Customer List
Table 66. Global Ipilimumab Sales Forecast by Region (2024-2029) & (KG)
Table 67. Global Ipilimumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Ipilimumab Sales Forecast by Country (2024-2029) & (KG)
Table 69. Americas Ipilimumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Ipilimumab Sales Forecast by Region (2024-2029) & (KG)
Table 71. APAC Ipilimumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Ipilimumab Sales Forecast by Country (2024-2029) & (KG)
Table 73. Europe Ipilimumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Ipilimumab Sales Forecast by Country (2024-2029) & (KG)
Table 75. Middle East & Africa Ipilimumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Ipilimumab Sales Forecast by Type (2024-2029) & (KG)
Table 77. Global Ipilimumab Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Ipilimumab Sales Forecast by Application (2024-2029) & (KG)
Table 79. Global Ipilimumab Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Gilead Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 81. Gilead Ipilimumab Product Portfolios and Specifications
Table 82. Gilead Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 83. Gilead Main Business
Table 84. Gilead Latest Developments
Table 85. BMS Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 86. BMS Ipilimumab Product Portfolios and Specifications
Table 87. BMS Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 88. BMS Main Business
Table 89. BMS Latest Developments
Table 90. Ono Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 91. Ono Ipilimumab Product Portfolios and Specifications
Table 92. Ono Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 93. Ono Main Business
Table 94. Ono Latest Developments
Table 95. Roche Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche Ipilimumab Product Portfolios and Specifications
Table 97. Roche Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 98. Roche Main Business
Table 99. Roche Latest Developments
Table 100. Prestige BioPharma Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 101. Prestige BioPharma Ipilimumab Product Portfolios and Specifications
Table 102. Prestige BioPharma Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 103. Prestige BioPharma Main Business
Table 104. Prestige BioPharma Latest Developments
Table 105. Avacta Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 106. Avacta Ipilimumab Product Portfolios and Specifications
Table 107. Avacta Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 108. Avacta Main Business
Table 109. Avacta Latest Developments
Table 110. Baxter Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 111. Baxter Ipilimumab Product Portfolios and Specifications
Table 112. Baxter Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 113. Baxter Main Business
Table 114. Baxter Latest Developments
Table 115. Shenyang Sansheng Pharmaceutical Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 116. Shenyang Sansheng Pharmaceutical Ipilimumab Product Portfolios and Specifications
Table 117. Shenyang Sansheng Pharmaceutical Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 118. Shenyang Sansheng Pharmaceutical Main Business
Table 119. Shenyang Sansheng Pharmaceutical Latest Developments
Table 1. Ipilimumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Ipilimumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of PD - L1 Antagonists
Table 4. Major Players of CTLA4 Antagonists
Table 5. Major Players of Immunocheckpoint Inhibitors
Table 6. Major Players of Other
Table 7. Global Ipilimumab Sales by Type (2018-2023) & (KG)
Table 8. Global Ipilimumab Sales Market Share by Type (2018-2023)
Table 9. Global Ipilimumab Revenue by Type (2018-2023) & ($ million)
Table 10. Global Ipilimumab Revenue Market Share by Type (2018-2023)
Table 11. Global Ipilimumab Sale Price by Type (2018-2023) & (US$/G)
Table 12. Global Ipilimumab Sales by Application (2018-2023) & (KG)
Table 13. Global Ipilimumab Sales Market Share by Application (2018-2023)
Table 14. Global Ipilimumab Revenue by Application (2018-2023)
Table 15. Global Ipilimumab Revenue Market Share by Application (2018-2023)
Table 16. Global Ipilimumab Sale Price by Application (2018-2023) & (US$/G)
Table 17. Global Ipilimumab Sales by Company (2018-2023) & (KG)
Table 18. Global Ipilimumab Sales Market Share by Company (2018-2023)
Table 19. Global Ipilimumab Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Ipilimumab Revenue Market Share by Company (2018-2023)
Table 21. Global Ipilimumab Sale Price by Company (2018-2023) & (US$/G)
Table 22. Key Manufacturers Ipilimumab Producing Area Distribution and Sales Area
Table 23. Players Ipilimumab Products Offered
Table 24. Ipilimumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Ipilimumab Sales by Geographic Region (2018-2023) & (KG)
Table 28. Global Ipilimumab Sales Market Share Geographic Region (2018-2023)
Table 29. Global Ipilimumab Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Ipilimumab Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Ipilimumab Sales by Country/Region (2018-2023) & (KG)
Table 32. Global Ipilimumab Sales Market Share by Country/Region (2018-2023)
Table 33. Global Ipilimumab Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Ipilimumab Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Ipilimumab Sales by Country (2018-2023) & (KG)
Table 36. Americas Ipilimumab Sales Market Share by Country (2018-2023)
Table 37. Americas Ipilimumab Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Ipilimumab Revenue Market Share by Country (2018-2023)
Table 39. Americas Ipilimumab Sales by Type (2018-2023) & (KG)
Table 40. Americas Ipilimumab Sales by Application (2018-2023) & (KG)
Table 41. APAC Ipilimumab Sales by Region (2018-2023) & (KG)
Table 42. APAC Ipilimumab Sales Market Share by Region (2018-2023)
Table 43. APAC Ipilimumab Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Ipilimumab Revenue Market Share by Region (2018-2023)
Table 45. APAC Ipilimumab Sales by Type (2018-2023) & (KG)
Table 46. APAC Ipilimumab Sales by Application (2018-2023) & (KG)
Table 47. Europe Ipilimumab Sales by Country (2018-2023) & (KG)
Table 48. Europe Ipilimumab Sales Market Share by Country (2018-2023)
Table 49. Europe Ipilimumab Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Ipilimumab Revenue Market Share by Country (2018-2023)
Table 51. Europe Ipilimumab Sales by Type (2018-2023) & (KG)
Table 52. Europe Ipilimumab Sales by Application (2018-2023) & (KG)
Table 53. Middle East & Africa Ipilimumab Sales by Country (2018-2023) & (KG)
Table 54. Middle East & Africa Ipilimumab Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Ipilimumab Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Ipilimumab Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Ipilimumab Sales by Type (2018-2023) & (KG)
Table 58. Middle East & Africa Ipilimumab Sales by Application (2018-2023) & (KG)
Table 59. Key Market Drivers & Growth Opportunities of Ipilimumab
Table 60. Key Market Challenges & Risks of Ipilimumab
Table 61. Key Industry Trends of Ipilimumab
Table 62. Ipilimumab Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Ipilimumab Distributors List
Table 65. Ipilimumab Customer List
Table 66. Global Ipilimumab Sales Forecast by Region (2024-2029) & (KG)
Table 67. Global Ipilimumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Ipilimumab Sales Forecast by Country (2024-2029) & (KG)
Table 69. Americas Ipilimumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Ipilimumab Sales Forecast by Region (2024-2029) & (KG)
Table 71. APAC Ipilimumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Ipilimumab Sales Forecast by Country (2024-2029) & (KG)
Table 73. Europe Ipilimumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Ipilimumab Sales Forecast by Country (2024-2029) & (KG)
Table 75. Middle East & Africa Ipilimumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Ipilimumab Sales Forecast by Type (2024-2029) & (KG)
Table 77. Global Ipilimumab Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Ipilimumab Sales Forecast by Application (2024-2029) & (KG)
Table 79. Global Ipilimumab Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Gilead Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 81. Gilead Ipilimumab Product Portfolios and Specifications
Table 82. Gilead Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 83. Gilead Main Business
Table 84. Gilead Latest Developments
Table 85. BMS Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 86. BMS Ipilimumab Product Portfolios and Specifications
Table 87. BMS Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 88. BMS Main Business
Table 89. BMS Latest Developments
Table 90. Ono Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 91. Ono Ipilimumab Product Portfolios and Specifications
Table 92. Ono Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 93. Ono Main Business
Table 94. Ono Latest Developments
Table 95. Roche Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche Ipilimumab Product Portfolios and Specifications
Table 97. Roche Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 98. Roche Main Business
Table 99. Roche Latest Developments
Table 100. Prestige BioPharma Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 101. Prestige BioPharma Ipilimumab Product Portfolios and Specifications
Table 102. Prestige BioPharma Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 103. Prestige BioPharma Main Business
Table 104. Prestige BioPharma Latest Developments
Table 105. Avacta Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 106. Avacta Ipilimumab Product Portfolios and Specifications
Table 107. Avacta Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 108. Avacta Main Business
Table 109. Avacta Latest Developments
Table 110. Baxter Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 111. Baxter Ipilimumab Product Portfolios and Specifications
Table 112. Baxter Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 113. Baxter Main Business
Table 114. Baxter Latest Developments
Table 115. Shenyang Sansheng Pharmaceutical Basic Information, Ipilimumab Manufacturing Base, Sales Area and Its Competitors
Table 116. Shenyang Sansheng Pharmaceutical Ipilimumab Product Portfolios and Specifications
Table 117. Shenyang Sansheng Pharmaceutical Ipilimumab Sales (KG), Revenue ($ Million), Price (US$/G) and Gross Margin (2018-2023)
Table 118. Shenyang Sansheng Pharmaceutical Main Business
Table 119. Shenyang Sansheng Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Ipilimumab
Figure 2. Ipilimumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ipilimumab Sales Growth Rate 2018-2029 (KG)
Figure 7. Global Ipilimumab Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Ipilimumab Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of PD - L1 Antagonists
Figure 10. Product Picture of CTLA4 Antagonists
Figure 11. Product Picture of Immunocheckpoint Inhibitors
Figure 12. Product Picture of Other
Figure 13. Global Ipilimumab Sales Market Share by Type in 2022
Figure 14. Global Ipilimumab Revenue Market Share by Type (2018-2023)
Figure 15. Ipilimumab Consumed in Cancer
Figure 16. Global Ipilimumab Market: Cancer (2018-2023) & (KG)
Figure 17. Ipilimumab Consumed in Melanoma
Figure 18. Global Ipilimumab Market: Melanoma (2018-2023) & (KG)
Figure 19. Global Ipilimumab Sales Market Share by Application (2022)
Figure 20. Global Ipilimumab Revenue Market Share by Application in 2022
Figure 21. Ipilimumab Sales Market by Company in 2022 (KG)
Figure 22. Global Ipilimumab Sales Market Share by Company in 2022
Figure 23. Ipilimumab Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Ipilimumab Revenue Market Share by Company in 2022
Figure 25. Global Ipilimumab Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Ipilimumab Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Ipilimumab Sales 2018-2023 (KG)
Figure 28. Americas Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 29. APAC Ipilimumab Sales 2018-2023 (KG)
Figure 30. APAC Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 31. Europe Ipilimumab Sales 2018-2023 (KG)
Figure 32. Europe Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Ipilimumab Sales 2018-2023 (KG)
Figure 34. Middle East & Africa Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 35. Americas Ipilimumab Sales Market Share by Country in 2022
Figure 36. Americas Ipilimumab Revenue Market Share by Country in 2022
Figure 37. Americas Ipilimumab Sales Market Share by Type (2018-2023)
Figure 38. Americas Ipilimumab Sales Market Share by Application (2018-2023)
Figure 39. United States Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Ipilimumab Sales Market Share by Region in 2022
Figure 44. APAC Ipilimumab Revenue Market Share by Regions in 2022
Figure 45. APAC Ipilimumab Sales Market Share by Type (2018-2023)
Figure 46. APAC Ipilimumab Sales Market Share by Application (2018-2023)
Figure 47. China Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Ipilimumab Sales Market Share by Country in 2022
Figure 55. Europe Ipilimumab Revenue Market Share by Country in 2022
Figure 56. Europe Ipilimumab Sales Market Share by Type (2018-2023)
Figure 57. Europe Ipilimumab Sales Market Share by Application (2018-2023)
Figure 58. Germany Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Ipilimumab Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Ipilimumab Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Ipilimumab Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Ipilimumab Sales Market Share by Application (2018-2023)
Figure 67. Egypt Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Ipilimumab in 2022
Figure 73. Manufacturing Process Analysis of Ipilimumab
Figure 74. Industry Chain Structure of Ipilimumab
Figure 75. Channels of Distribution
Figure 76. Global Ipilimumab Sales Market Forecast by Region (2024-2029)
Figure 77. Global Ipilimumab Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Ipilimumab Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Ipilimumab Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Ipilimumab Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Ipilimumab Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Ipilimumab
Figure 2. Ipilimumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ipilimumab Sales Growth Rate 2018-2029 (KG)
Figure 7. Global Ipilimumab Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Ipilimumab Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of PD - L1 Antagonists
Figure 10. Product Picture of CTLA4 Antagonists
Figure 11. Product Picture of Immunocheckpoint Inhibitors
Figure 12. Product Picture of Other
Figure 13. Global Ipilimumab Sales Market Share by Type in 2022
Figure 14. Global Ipilimumab Revenue Market Share by Type (2018-2023)
Figure 15. Ipilimumab Consumed in Cancer
Figure 16. Global Ipilimumab Market: Cancer (2018-2023) & (KG)
Figure 17. Ipilimumab Consumed in Melanoma
Figure 18. Global Ipilimumab Market: Melanoma (2018-2023) & (KG)
Figure 19. Global Ipilimumab Sales Market Share by Application (2022)
Figure 20. Global Ipilimumab Revenue Market Share by Application in 2022
Figure 21. Ipilimumab Sales Market by Company in 2022 (KG)
Figure 22. Global Ipilimumab Sales Market Share by Company in 2022
Figure 23. Ipilimumab Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Ipilimumab Revenue Market Share by Company in 2022
Figure 25. Global Ipilimumab Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Ipilimumab Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Ipilimumab Sales 2018-2023 (KG)
Figure 28. Americas Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 29. APAC Ipilimumab Sales 2018-2023 (KG)
Figure 30. APAC Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 31. Europe Ipilimumab Sales 2018-2023 (KG)
Figure 32. Europe Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Ipilimumab Sales 2018-2023 (KG)
Figure 34. Middle East & Africa Ipilimumab Revenue 2018-2023 ($ Millions)
Figure 35. Americas Ipilimumab Sales Market Share by Country in 2022
Figure 36. Americas Ipilimumab Revenue Market Share by Country in 2022
Figure 37. Americas Ipilimumab Sales Market Share by Type (2018-2023)
Figure 38. Americas Ipilimumab Sales Market Share by Application (2018-2023)
Figure 39. United States Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Ipilimumab Sales Market Share by Region in 2022
Figure 44. APAC Ipilimumab Revenue Market Share by Regions in 2022
Figure 45. APAC Ipilimumab Sales Market Share by Type (2018-2023)
Figure 46. APAC Ipilimumab Sales Market Share by Application (2018-2023)
Figure 47. China Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Ipilimumab Sales Market Share by Country in 2022
Figure 55. Europe Ipilimumab Revenue Market Share by Country in 2022
Figure 56. Europe Ipilimumab Sales Market Share by Type (2018-2023)
Figure 57. Europe Ipilimumab Sales Market Share by Application (2018-2023)
Figure 58. Germany Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Ipilimumab Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Ipilimumab Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Ipilimumab Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Ipilimumab Sales Market Share by Application (2018-2023)
Figure 67. Egypt Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Ipilimumab Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Ipilimumab in 2022
Figure 73. Manufacturing Process Analysis of Ipilimumab
Figure 74. Industry Chain Structure of Ipilimumab
Figure 75. Channels of Distribution
Figure 76. Global Ipilimumab Sales Market Forecast by Region (2024-2029)
Figure 77. Global Ipilimumab Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Ipilimumab Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Ipilimumab Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Ipilimumab Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Ipilimumab Revenue Market Share Forecast by Application (2024-2029)
